Connect with us

EU

Is #Coffee worth saving?

Guest contributor

Published

on

Saudi society is changing rapidly. Women have been allowed, and movie theaters have returned to the kingdom. The international community has, rightly, been supportive of these initiatives, writes Joseph Hammond. 

Yet, there are elements of traditional Saudi society worth preserving, which also need international support. One of these is the country’s unique coffee culture.

Coffee is a permanent fixture of Arabian culture which is served everywhere from small cups at wedding celebrations to gatherings by camp-fires flickering under the starry night sky.

From flat whites to modern concoctions like the beloved pumpkin-spiced latte coffee is now a global phenomenon. Yet, Arabia was once so central to the worldwide coffee trade that the port of Mokha, Yemen gave its name to the chocolatey "mocha coffee" found around the world.

After decades of war, Yemen has only recently having revived its ancient tradition of coffee cultivation. Environmentalists should cheer a Yemeni switch from khat to Coffee. Khat, a chewable leafy green stimulant and a thirsty crop, is contributing to Yemen's water crisis.

Across the border, Saudi Arabia is one of the largest coffee producers of the fabled Arabica coffee. The mountainous region of Jazan, located in the southern-most part which borders Yemen, has been producing "black gold" in the form of prize coffee long before it struck oil.  Khawlani coffee production stretches back over three centuries.

Named after the ancient Arab tribe of Khawlan, the tradition of coffee cultivation has been passed down from generation to generation and is continued today by 700 farmers.

Since 2017, the Saudi Heritage Preservation Society has fought to protect the cultivation of the Khawlani bean. Processing the Khawlani bean can be an arduous process. Planted, harvested and processed painstakingly by hand, the Khawlani bean plant can take up to three years to bear fruit. This year the Saudi Heritage Preservation Society has made a formal request to UNESCO for the protection of this ancient Khawlani cultivation method of coffee.

Recognizing Khawlani coffee production comes at a time that other countries are seeking recognition for their unique coffee culture.  Concurrently Italy has asked UNESCO to protect Italian expresso culture. A venture which is somewhat controversial in Italy, as recent years has seen a race to the bottom in terms of quality as vendors have sought to keep the price of one euro. Others suggest such a designation will hurt the evolution of expresso. Still, Italy's chances remain relatively high after traditional Napoli pizza preparation received UNESCO protection in 2017.

Coffee is as important to the Islamic world as pizza is to Italian culture (if not more).

Within the Muslim world, coffee is not merely a beverage to be drunk. Once referred to as the "wine of Islam. During the Middle Ages, the Sufis and other pious Muslims would stay up late praying aided by coffee. In doing so, coffee overcame the opposition of some Muslim leaders such as a ban imposed by the Turkish Sultan Murad the Fifth. In 2013, Turkey advocated successfully to have Turkish coffee culture receive UNESCO protection.

Similarly, many Christian leaders at first opposed what they saw as a Muslim Trojan horse. Years later then Pope Clement VIII sampled it for the first time and had a change of heart. "This Satan's drink is so delicious that it would be a pity to let the infidels have exclusive use of it" he supposedly said. Today it is the world's stimulant of choice.

Surely, UNESCO in the coming months has many important issues on its plate from protecting historic structures to the development of sustainable cities. Yet, still this  organization and it's Secretary-General, Audrey Azoulay (who is herself of Moroccan origin) - have time for a coffee break.

EU

A social and human rights pillar to the India-EU map to 2025

Guest contributor

Published

on

Imagine if the announcement on waiving the intellectual property rights of the COVID-19 vaccines would have come from Brussels rather than Washington, writes Simone Galimberti.

Maybe just the day before the EU-India Summit in Porto or perhaps it could have been announced live during the virtual summit.

India, with South Africa, took a leading role in demanding an uplifting of the patents’ rights but till the Biden administration announcement, their request was always rejected and the EU was among those vocally defending big pharma patents’ rights.

With the Biden White House policy reversal, the Europeans wasted a gold opportunity that could have eased their way into raising less glamorous but certainly important topics for an EU that professes to live up to certain values embraced as foundational to its external relation work.

Instead, while all the attention over the summit is veering towards trade and green investments, we are running the risk of overlooking the rights and social dimensions of the relationship between the India and the EU.

Talking about human rights, in particular, is going to be a tricky task for the EU leaders because is an issue where Prime Minister Modi is not going to be so accommodative nor inclined to act.

It is true that recently a low key 9th EU-India Human Rights Dialogue was held in Delhi, an instrument that was reactivated after seven years but the level of commitment of the EU towards universal rights should find a much bigger space than the just two short paragraph found in the latest strategic document endorsed by both parties, the EU-India Strategic Partnership: A road map to 2025.

Fortunately the European Parliament, despite some shenanigans amid pressure from the India Embassy to the European Union, issued a recommendation on the 29th of April 2021 expressing its concerns over the situation of human rights in India.

In a speech on 29 April on behalf of High Representative/Vice-President Josep Borrell at the European Parliament, Ylva Johansson, Commissioner for Home Affairs said “Human rights and democratic values are also at the heart of our engagement with India. Let me assure you that the European Union raises these matters with India through different channel”.

The EU Leaders should take this statement to the letter but, though soft attempts at raising the issue will be certainly made by the Europeans during the summit, we cannot reasonably expect them to do the heavy lifting on this despite widespread criticism around the world and with some of the major human rights organizations launching an appeal to the EU to take human rights seriously while dealing with India.

Given the fact that the EU must elevate its relationship with India, what could be the most effective formula to do that?

In addition to discussions at political levels, human rights should be vigorously tackled at multiple levels through interactions by experts and practitioners in Track II format initiatives but also through a bottom up “people to people” human rights agenda with more support for grassroots rights defenders.

At the same time a stronger “official” voice from Brussels needs to be raised when serious abuses occur, be the worrying developments on the Citizenship Amendment Act or a national registry of citizenship registry or the unjust imprisonment an octogenarian Jesuit activist priest or the recent forced closing of the Amnesty International office last September without mentioning the abuses happening in Kashmir.

Complementary to pursuit a bolder human rights agenda, embracing other dimensions of a broader India and EU social agenda is not only paramount on its own but can also reinforce the former.

For example, a rethinking of the EU-India Forum that last time was held in 2012 could be a first step.

Besides its Track II dimension that should be strengthened and enlarged, the Forum could become an overarching framework with an ambitious civil society agenda founded on continuous opportunities for interactions and exchange among people, especially youths, especially now that webinars and virtual conference have become a new norm.

More youth engagement among youth could lead, with some vision, to an 'India-EU Youth Strategy', creating a new level of bilateral ambitions focused on the future generations.

New programs are needed but also existing initiatives could be dusted off and revitalized in order to lay the foundations for such youth strategy.

For example, it will be significant to revamp the Joint Declaration on Common Agenda on Migration and Mobility (CAMM), giving a boost to students and young professional mobility, including exchange programs, mutual recognition of academic qualifications and recognition of academic skills.

In addition, can the EU find among its Foreign Policy Instruments, FPI, the adequate financial space for a major boost in funding for a new 'Tagore -Erasmus Programme', allowing a quantum leap in the student exchange between Indian and Europe?

Another area of interest would be for the EU member states to carve out, from the broader and much more complex to negotiate migration pact, the revamping of the EU Blue Card, a scheme that in theory attracts in the common European job market young professionals from third states that it is still well below its potential.

While in the area of research and analysis, a dynamic partnership among think tanks, the EU-India Think Tanks Twinning Initiative, is currently being undertaken, what could be done to better include and involve Indian universities in the Horizon Europe, the European Research Council, the Marie Sklodowska-Curie fellowship programs as suggested in the recently released report by the European Parliament concerning the future of EU-India relations?

The European University Initiative that enables cross nations consortia of universities within the EU could encourage, with additional grants, collaborations and exchange programs with Indian counterparts, laying the stones for broader initiatives in what could become a Joint Indo European Educational Area.

Imagining a new and different India - EU relationship requires ambition.

The EU has successfully managed to move past a narrow mono dimensional approach to its partnership with India, shifting from on aid assistance frame then upgraded into a broader economic framework.

With security and defense now dominating the agenda together with trade and investment, there is a need to create additional layers for what could become a true force for the promotion of multilateralism, enhancing a potential geopolitical partnership that can become a model for others like minded democracies to follow.

Yet, it won’t be possible to achieve such deep and ingrained level of cooperation without a steadfast commitment for shared values based on trust and the adequate “intimacy” and comfort indispensable to express divergent opinions, including the willingness to share and absorb criticisms based on fairness and equality among partners.

While Prime Minister Modi should rightly not refrain himself from his disappointment over the EU’s position in relation to the vaccines’ patents, the EU leaders should not shy away from embracing an effective social agenda centered around human rights, human development and more educational opportunities for youth.

Thinking about it, there is no better place of doing it than in Porto where the EU leaders will try to chart a new course for strengthening its social union.

The summit can be remembered for adding a new layer to the cooperation with India, one centered on the respects of universal rights and shared values.

Certainly, the EU-India Strategic Partnership: A road map to 2025 is in need of some bold changes.

Simone Galimberti is based in Kathmandu. He writes on social inclusion, youth development, regional integration and the SDGs in the context of Asia Pacific.

Continue Reading

coronavirus

Therapeutics Strategy - First rolling review of a new COVID-19 medicine

EU Reporter Correspondent

Published

on

The European Medicines Agency has today (7 May) started the rolling review of sotrovimab (VIR-7831), a monoclonal antibody developed for the treatment of COVID-19. The review follows hot on the heels of the EU COVID-19 Therapeutics Strategy presented yesterday and is a first step towards the Strategy's target of starting seven rolling reviews of COVID-19 therapeutics in 2021. The rolling review launched by EMA will assess sotrovimab's effectiveness in preventing hospitalization and death; safety and quality. A rolling review is quicker than a regular evaluation as data is reviewed as it comes in. Should the European Medicines Agency recommend authorising the treatment at the end of its review, the European Commission will move swiftly to authorize it. 

The EU Therapeutics Strategy supports the development and availability of much needed COVID-19 therapeutics and covers the lifecycle of medicines: from research, development and manufacturing to procurement and deployment. It is part of the strong European Health Union, in which all EU countries prepare and respond together to health crises and ensure the availability of affordable and innovative medical supplies – including the therapeutics needed to treat COVID-19. More details on the EU Therapeutics Strategy are available in a press release and factsheet.

Continue Reading

Cancer

EAPM: Stronger together against cancer and with good data sharing

Avatar

Published

on

Good morning, one and all, and welcome to the European Alliance for Personalised Medicine (EAPM) update – there is much positivity concerning the battle against cancer and the consultation on the health data sharing plan, so some refreshing good news after all the recent COVID-related despondency, writes EAPM Executive Director Dr. Denis Horgan.

Porto Declaration on Cancer Research

The Porto Declaration on Cancer Research was launched during the European Cancer Research Summit 2021, held on 3 May at the Portuguese Institute of Oncology (IPO) in Porto under the Portuguese Presidency of the Council of the European Union.

The declaration presented by Portuguese Minister Manuel Heitor is the result of the work done by several researchers, scientific and clinical leaders and political decision-makers, who have reinforced the need to broaden Europe's Beating Cancer Plan over recent months, particularly through extending and reinforcing the European network of Comprehensive Cancer Centres (CCCs), based on the reinforcement of three types of research infrastructure:

Translational research infrastructure
Clinical and prevention trial infrastructure
Outcomes research infrastructure

These infrastructure components are increasingly being deemed critical to prevention, early detection, diagnosis, treatment, monitoring disease treatment and patient support and assistance. National participation in the European network of Comprehensive Cancer Centres is led in Portugal by the “Porto Comprehensive Cancer Centre”, based in the Porto IPO, in partnership with its associated laboratory, i3S, which recently received funding of around EUR 15 million for new equipment under the North Regional Operational Programme.

The Porto Declaration on Cancer Research strengthens the commitment of the Trio Presidency of the Council of the European Union (Germany, Portugal and Slovenia) to significantly reduce cancer mortality by 2030, with a goal of 75% of cancer patients in Europe surviving for at least 10 years. Ensuring this goal across Europe means reinforcing the development of a continuum of research activities, from basic to clinical research, including the reinforcement of the European network of Comprehensive Cancer Centres and the three research infrastructure components mentioned above, as well as active participation by the patients and their associations in order to mitigate social and economic inequalities.

The Porto Declaration on Cancer Research thus calls on all European citizens and their Member States to stimulate the synergies in the areas of regional, national and European funding so that cancer research infrastructure access will be easier and fairer.

Speaking at the Cancer Research Summit on 3 May, Health Commissioner Stella Kyriakides said that it’s key the Commission’s Cancer Plan “works hand in hand” with the Horizon Europe Mission on Cancer in order to “ensure coherence between research goals and policy objectives.”  screening program was suspended five years ago due to low turnout and needs to be upgraded, she explained. 

Consultation on health data sharing plan opened by Commission

On 3 May, the Commission published an open public consultation on the European Health Data Space (EHDS) - an important building block of the European Health Union. The EHDS aims to make full use of digital health to provide high-quality healthcare and reduce inequalities. It will promote access to health data for prevention, diagnosis and treatment, research and innovation, as well as for policy-making and legislation. The EHDS will place individuals' rights to control their own personal health data at its core. The consultation will remain open for responses until 26 July 2021. Health and Food Safety Commissioner Stella Kyriakides said: ″The European Health Data Space will be a crucial component of a strong European Health Union. It will enable EU-wide collaboration for better healthcare, better research and better health policy making. I invite all interested citizens and stakeholders to take part in the consultation and help us leverage the power of data for our health. This will have to rest on a strong foundation of non-negotiable citizens' rights, including privacy and data protection.″

Innovative solutions and digital technologies including artificial intelligence (AI), can transform healthcare systems. They make them more sustainable and improve people's health. The development of these technologies requires secure access by researchers and innovators to substantial amounts of health data.

This public consultation focuses on:

the access to and use of health data for healthcare provision, research and innovation, policy-making and regulatory decision;

fostering a genuine single market for digital health services and products, including innovative ones.

The creation of a European Health Data Space is one the key priorities of this Commission in the area of health. The purpose of the EHDS is to promote health-data exchange and support research on new preventive strategies, as well as on treatments, medicines, medical devices and outcomes. In the Communication on the European Strategy for Data, the Commission announced its objective to deliver concrete results in the area of health data and to understand the potential generated by developments in digital technologies. The collection, access, storage, use and re-use of data in healthcare present specific challenges that need to be addressed.

This requires a regulatory framework that best serves individuals' interests and rights, especially as regards the processing of sensitive personal health data. In this context, the Commission adopted its Data Governance Act proposal (2020) with conditions regarding access to data, and provisions to foster trust in voluntary data sharing. Facilitating better access to, and exchange of, health data is essential to ensure increased accessibility, availability and affordability of healthcare. It will stimulate innovation in health and care for better treatment and outcomes, and encourage innovative solutions that make use of digital technologies, including AI.

Health commissioner offers sweeping ambitions for pharma reform and health committee publishes draft response to pharma strategy

No patient in Europe should have to go without medicines that he or she needs due to money or other obstacles, Health Commissioner Stella Kyriakides has said. 

Speaking at an event organized by the European Commission and the Portuguese EU presidency, Kyriakides pledged that EU’s pharmaceutical strategy will tackle the core issues that make medicines unavailable to those who need them. 

The strategy will culminate with a legislative proposal, planned for 2022, revising the EU’s basic pharma rules, which will open the door to the overhaul. 

Kyriakides’ willingness to tear up the current rules may make drugmakers nervous, since they rely on perks like market exclusivity to protect their bottom line. The 2022 reform will take into account “the relationship with intellectual property rights to address aspects that impede the competitive functioning of markets,” she noted. “The failures of markets should not be the failures of our health systems.”

The European Parliament’s Committee on the Environment, Public Health and Food Safety has published a draft response to the Commission’s Pharmaceutical Strategy. The draft report is authored by Spanish MEP Dolors Montserrat from the European People’s Party who is rapporteur for the pharmaceutical strategy. The document calls on the Commission to push ahead with a number of priorities that it identified in the pharmaceutical strategy, which it published in November. Among the demands made in the draft is a call on the Commission “to incorporate new criteria into the system of incentives for research into and the development of new medicines for unmet therapeutic needs.” It also asks the Commission to review incentives and improve price transparency.

EU pharma vulnerabilities

The executive arm of the European Union on Wednesday (5 May) moved to reduce the bloc's dependence on foreign supplies of products in key fields such as pharmaceuticals and digital technology. The initiative forms part of an updated industrial strategy aimed at strengthening the EU's single market, and was presented alongside a proposal for new regulations to tackle distortions caused by foreign subsidies in the bloc.

The European Commission's new industrial strategy is an update from one made in March 2020, before the World Health Organization declared COVID-19 a pandemic. Coronavirus has wreaked havoc in the 27-member EU, making itaware that over-reliance on imports for key components such as those required in drug production and semiconductors could disrupt entire sectors.

"We are updating our industrial strategy, applying the knowledge we have accumulated during the pandemic, drawing on lessons learned and the available evidence," European Commission Executive Vice President Valdis Dombrovskis told a news conference on Wednesday. He said that three key factors have influenced the thinking on the new strategy. The pandemic has highlighted some fragilities in the single market when exposed to particular types of disruption. There has been a growing trend in many jurisdictions to analyze vulnerabilities in key strategic value chains. And the business case for the EU's green and digital transition has become even stronger, Dombrovskis said.

Europe depends on third countries, primarily China and India, in its pharmaceutical supply chains, according to a Commission staff working document.

WHO’s emergencies programme ‘can't deal with multiple crises’

The coronavirus pandemic has revealed that the World Health Organization’s health emergencies programme is “inadequately equipped to deal with a global pandemic while simultaneously responding to other emergencies”, with chronic under-funding and under-staffing leaving it overstretched in some areas, a new report has found.

The report, penned by the Independent Oversight and Advisory Committee for the WHO’s health emergencies programme, covers May 2020 to April 2021 and will be presented at the World Health Assembly later this month. The committee is chaired by Felicity Harvey, a visiting professor at Imperial College London’s Institute of Global Health Innovation.

The programme had to leverage the entire organization during the pandemic and strengthen partnerships with member countries and expert groups to overcome those challenges, the panel found.

The report made specific mention of the Access to COVID-19 Tools Accelerator, of which COVAX is part of, noting that it has “struggled with shortfalls of political will and global solidarity, limited production capacity of vaccines and insufficient financial investment.”

Digital Green Certificate

The EU’s so-called COVID passport – the Digital Green Certificate – to travel freely during the pandemic should be ready for use from the end of June, according to Justice Commissioner Didier Reynders. At the Committee on Civil Liberties, Justice and Home Affairs (LIBE) of the European Parliament on Tuesday (4 May), Reynders said that the certificate will be in use before the summer. “We want to ensure that all EU citizens receive the same treatment when member states lift restrictions on free movement for holders of vaccines, recovery or test certificates,” he said. Last month, the European Commission presented its proposal for the certificate, which will provide proof that a person has been vaccinated against COVID-19, has natural immunity from it, or has a recent negative test result.

On 26 March, the European Parliament launched an accelerated procedure to fast-track the certificate’s approval, and the Parliament and the Member States are currently negotiating the practical details. In principle, however, the individual member states decide which consequences are attached to the document. These could include, for example, free access to the territory without mandatory quarantine.

And that is all from EAPM for this week – stay safe, stay well, have an excellent weekend, and see you next week.

Continue Reading

Twitter

Facebook

Trending